Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy United Therapeutics Corporation stock

Own United Therapeutics Corporation stock in just a few minutes.

United Therapeutics Corporation is a biotechnology business based in the US. United Therapeutics Corporation shares (UTHR) are listed on the NASDAQ and all prices are listed in US Dollars. United Therapeutics Corporation employs 950 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in United Therapeutics Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – UTHR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

United Therapeutics Corporation share price

Use our graph to track the performance of UTHR stocks over time.

United Therapeutics Corporation shares at a glance

Information last updated 2021-04-23.
52-week range$98.37 - $212.62
50-day moving average $180.40
200-day moving average $154.89
Wall St. target price$205.44
PE ratio 18.1395
Dividend yield N/A (0%)
Earnings per share (TTM) $11.54

Buy United Therapeutics Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy United Therapeutics Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is United Therapeutics Corporation under- or over-valued?

Valuing United Therapeutics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United Therapeutics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

United Therapeutics Corporation's P/E ratio

United Therapeutics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, United Therapeutics Corporation shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

United Therapeutics Corporation's PEG ratio

United Therapeutics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 7.8048. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into United Therapeutics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

United Therapeutics Corporation's EBITDA

United Therapeutics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $640.9 million.

The EBITDA is a measure of a United Therapeutics Corporation's overall financial performance and is widely used to measure a its profitability.

United Therapeutics Corporation financials

Revenue TTM $1.5 billion
Operating margin TTM 39.84%
Gross profit TTM $1.4 billion
Return on assets TTM 8.66%
Return on equity TTM 16.67%
Profit margin 34.71%
Book value $76.28
Market capitalisation $9.4 billion

TTM: trailing 12 months

Shorting United Therapeutics Corporation shares

There are currently 2.3 million United Therapeutics Corporation shares held short by investors – that's known as United Therapeutics Corporation's "short interest". This figure is 2.7% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting United Therapeutics Corporation shares can be evaluated.

United Therapeutics Corporation's "short interest ratio" (SIR)

United Therapeutics Corporation's "short interest ratio" (SIR) is the quantity of United Therapeutics Corporation shares currently shorted divided by the average quantity of United Therapeutics Corporation shares traded daily (recently around 370809.84126984). United Therapeutics Corporation's SIR currently stands at 6.3. In other words for every 100,000 United Therapeutics Corporation shares traded daily on the market, roughly 6300 shares are currently held short.

However United Therapeutics Corporation's short interest can also be evaluated against the total number of United Therapeutics Corporation shares, or, against the total number of tradable United Therapeutics Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case United Therapeutics Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 United Therapeutics Corporation shares in existence, roughly 50 shares are currently held short) or 0.0597% of the tradable shares (for every 100,000 tradable United Therapeutics Corporation shares, roughly 60 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against United Therapeutics Corporation.

Find out more about how you can short United Therapeutics Corporation stock.

United Therapeutics Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like United Therapeutics Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

United Therapeutics Corporation's total ESG risk score

Total ESG risk: 35.51

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and United Therapeutics Corporation's overall score of 35.51 (as at 12/31/2018) is nothing to write home about – landing it in it in the 54th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like United Therapeutics Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

United Therapeutics Corporation's environmental score

Environmental score: 6.16/100

United Therapeutics Corporation's environmental score of 6.16 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

United Therapeutics Corporation's social score

Social score: 24.94/100

United Therapeutics Corporation's social score of 24.94 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that United Therapeutics Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

United Therapeutics Corporation's governance score

Governance score: 17.41/100

United Therapeutics Corporation's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that United Therapeutics Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

United Therapeutics Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. United Therapeutics Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that United Therapeutics Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

United Therapeutics Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 35.51
Total ESG percentile 53.55
Environmental score 6.16
Environmental score percentile 9
Social score 24.94
Social score percentile 9
Governance score 17.41
Governance score percentile 9
Level of controversy 2

United Therapeutics Corporation share dividends

We're not expecting United Therapeutics Corporation to pay a dividend over the next 12 months.

Have United Therapeutics Corporation's shares ever split?

United Therapeutics Corporation's shares were split on a 2:1 basis on 22 September 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your United Therapeutics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for United Therapeutics Corporation shares which in turn could have impacted United Therapeutics Corporation's share price.

United Therapeutics Corporation share price volatility

Over the last 12 months, United Therapeutics Corporation's shares have ranged in value from as little as $98.37 up to $212.62. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United Therapeutics Corporation's is 0.4501. This would suggest that United Therapeutics Corporation's shares are less volatile than average (for this exchange).

United Therapeutics Corporation overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L. L. C.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site